Kodiak Sciences stock triples as Zenkuda matches Eylea in Phase 3 trial

Key points

• Kodiak Sciences stock jumped from $32.35 to $89.92, a 178% increase, following the release of Phase 3 trial data.
• The Daybreak trial compared Zenkuda (tarcocimab) and tabirafusp-ted to aflibercept, finding both candidates met the primary endpoint for vision gains.
• Zenkuda enabled over half of patients to maintain 24-week dosing intervals, compared to the standard eight-week schedule for aflibercept.
• The company intends to submit a multi-indication FDA application for Zenkuda in Q4 2026, including data from five Phase 3 trials.
• Tabirafusp-ted, a bispecific therapy, also matched aflibercept, though detailed comparative data remains pending post-hoc analysis.

Background

Kodiak Sciences previously halted Zenkuda development in 2023 due to an unexpected increase in cataracts but resumed trials later that year based on diabetic retinopathy data. This recent success marks a significant turnaround for the company, moving it closer to commercialization after previous setbacks.

How outlets are covering it

Fierce Biotech highlights the competitive landscape, noting that while the results are strong, Kodiak faces challenges from biosimilars and branded rivals like Eylea HD and Vabysmo. Yahoo Finance focuses primarily on the dramatic stock market reaction, emphasizing the 178% surge and the specific price points, whereas Fierce Biotech provides clinical context regarding the AI-guided dosing algorithm and safety profiles.

Why it matters

The success of Zenkuda could disrupt the market for anti-VEGF therapies by offering a treatment with significantly longer dosing intervals, potentially reducing the burden on patients and healthcare systems. A successful FDA filing would establish Kodiak as a major player in the ophthalmology sector.

What to watch

Kodiak Sciences will file for FDA approval of Zenkuda in the fourth quarter of 2026. The company will also conduct post-hoc analyses to identify patient subgroups that benefit most from tabirafusp-ted and continue Phase 3 trials for diabetic macular edema.